MTH-68/H oncolytic viral treatment in human high-grade gliomas
/in Glioblastoma, International Publications, Newcastle Disease VirusEnhancement of antitumor response to sarcoma 45 in rats by combination of whole-body hyperthermia and interleukin-2
/in Hyperthermia, International Publications, Soft Tissue SarcomaMicronutrient concentrations in patients with malignant disease: effect of the inflammatory response
/in International Publications, MicronutrientsVaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study
/in Breast Cancer, Dendritic Cells, International PublicationsDendritic cells pulsed with pancreatic cancer total tumor RNA generate specific antipancreatic cancer T cells
/in International Publications, Pancreatic CancerThyroglobulin-pulsed human monocyte-derived dendritic cells induce CD4+ T cell activation
/in Dendritic Cells, International Publications, Thyroid CancerDendritic cell-based therapeutics for breast cancer
/in Breast Cancer, Dendritic Cells, International PublicationsRadiotherapy and hyperthermia in the treatment of patients with locally advanced prostate cancer: preliminary results
/in Hyperthermia, International Publications, Prostate Cancer
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer